A photo of John Brewington.

Member, Division of Pulmonary Medicine

Assistant Professor, UC Department of Pediatrics


Board Certified

My Biography & Research


Dr. Brewington cares for patient with a wide variety of airway and lung diseases. He has a particular interest in the care of patients with cystic fibrosis, congenital airway malformations, and chronic respiratory failure. His research focuses primarily on cystic fibrosis, with a goal of maximizing the clinical benefits of new "modulator" drugs at the individual patient level. His work investigates possible drug-drug interactions between traditional CF therapies and these novel drugs, as well as personalized model systems to predict and study drug benefit for an individual patient. He is also interested in medical education, including residency and fellowship training, as well as formal training in flexible bronchoscopy.

Clinical Interests

Pulmonary medicine; bronchology; cystic fibrosis; congenital airway malformations

Research Interests

Cystic fibrosis; CFTR modulators; patient-derived model systems

Academic Affiliation

Assistant Professor, UC Department of Pediatrics


Pulmonary Medicine, Bronchoscopy, Pulmonary Medicine

My Education

MD: Wake Forest University, Winston-Salem, NC, 2009.

Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2012.

Chief Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2013.

Fellowship: Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2016.

Certification: Pediatrics, 2012; Pediatric Pulmonary Medicine, 2016.

My Publications

CRISPRi-mediated functional analysis of lung disease-associated loci at non-coding regions. Stuart, WD; Guo, M; Fink-Baldauf, IM; Coleman, AM; Clancy, JP; Mall, MA; Lim, F; Brewington, JJ; Maeda, Y. 2020; 2.

Clinically approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia. Borcherding, DC; Siefert, ME; Lin, S; Brewington, J; Sadek, H; Clancy, JP; Plafker, SM; Ziady, AG. Journal of Clinical Investigation. 2019; 129:3448-3463.

Direct Lung Sampling Indicates That Established Pathogens Dominate Early Infections in Children with Cystic Fibrosis. Jorth, P; Ehsan, Z; Rezayat, A; Caldwell, E; Pope, C; Brewington, JJ; Goss, CH; Benscoter, D; Clancy, JP; Singh, PK. Cell Reports. 2019; 27:1190-1204.e3.

Sweat Chloride Testing. McCarthy, C; Clancy, JP; Brewington, J. Journal of the American Medical Association. 2019; 321:701-702.

Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies. Brewington, JJ; Filbrandt, ET; III, LF J; Moncivaiz, JD; Ostmann, AJ; Strecker, LM; Clancy, JP. JCI insight. 2018; 3.

Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis. McCarthy, C; Brewington, JJ; Harkness, B; Clancy, JP; Trapnell, BC. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2018; 51:1702457-1702457.

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study. Brewington, JJ; Filbrandt, ET; III, LF J; Moncivaiz, JD; Ostmann, AJ; Strecker, LM; Clancy, JP. Jove-Journal of Visualized Experiments. 2018; 2018.

Chronic beta 2AR stimulation limits CFTR activation in human airway epithelia. Brewington, JJ; Backstrom, J; Feldman, A; Kramer, EL; Moncivaiz, JO; Ostmann, AJ; Zhu, X; Lu, LJ; Clancy, JP. JCI insight. 2018; 3.

Detection of CFTR function and modulation in primary human nasal cell spheroids. Brewington, JJ; Filbrandt, ET; III, LF J; Ostinann, AJ; Strecker, LM; Szczesniak, RD; Clancy, JP. Journal of Cystic Fibrosis. 2018; 17:26-33.

CFTR functional assays in drug development. Zak, SM; Clancy, JP; Brewington, JJ. Expert Opinion on Orphan Drugs. 2017; 5:889-898.